20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Bridgewater, United States with about 8,700 employees. Its market capitalization is roughly $7 billion. In the fiscal year ended 2025-12-31, AMRX reported $3.0B in revenue and $72M in net income.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
Interactive charts & full statements → Open the AMRX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $3.1B | $3.0B | $2.8B | $2.4B | $2.2B | $2.1B | $2.0B | $1.6B | $1.7B | $1.0B | $1.0B | $866M | $786M |
| Gross Profit | $1.2B | $1.1B | $1.0B | $864M | $791M | $769M | $628M | $353M | $716M | $526M | $597M | $499M | $450M |
| Gross Margin % | 39.3% | 37.6% | 36.5% | 36.1% | 35.8% | 36.7% | 31.5% | 21.7% | 43.1% | 50.9% | 58.7% | 57.6% | 57.2% |
| Operating Income (EBIT) | $403M | $423M | $249M | $204M | ($95M) | $153M | $91M | ($249M) | ($20M) | $245M | $285M | $227M | $223M |
| Operating Margin % | 12.9% | 14.0% | 8.9% | 8.5% | -4.3% | 7.3% | 4.6% | -15.3% | -1.2% | 23.7% | 28.0% | 26.2% | 28.4% |
| Net Income | $157M | $72M | ($117M) | ($84M) | ($130M) | $11M | $91M | ($362M) | ($170M) | $168M | $207M | $169M | $177M |
| Net Margin % | 5.1% | 2.4% | -4.2% | -3.5% | -5.9% | 0.5% | 4.6% | -22.2% | -10.2% | 16.2% | 20.4% | 19.6% | 22.5% |
| EBITDA | $652M | $604M | $440M | $501M | $440M | $401M | $346M | $155M | ($20M) | $271M | $307M | $253M | $243M |
| Earnings Per Share (EPS) | $0.48 | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.61 | $-2.74 | $-1.33 | $1.46 | $1.10 | $0.90 | $0.94 |
| Shares Outstanding (M) | 328M | 325M | 309M | 176M | 151M | 152M | 149M | 132M | 127M | 115M | 189M | 189M | 189M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $796M | $723M | $814M | $785M | $725M | $695M | $731M | $702M |
| Gross Profit | $335M | $320M | $297M | $274M | $286M | $256M | $263M | $270M |
| Gross Margin % | 42.0% | 44.3% | 36.5% | 34.9% | 39.5% | 36.8% | 36.0% | 38.4% |
| Operating Income (EBIT) | $146M | $143M | $115M | $0M | $111M | $100M | $76M | $89M |
| Operating Margin % | 18.3% | 19.8% | 14.1% | -0.0% | 15.4% | 14.4% | 10.4% | 12.6% |
| Net Income | $58M | $62M | $35M | $2M | $22M | $12M | ($31M) | $0M |
| Net Margin % | 7.2% | 8.6% | 4.3% | 0.3% | 3.1% | 1.8% | -4.2% | -0.0% |
| EBITDA | $194M | $186M | $161M | $112M | $177M | $155M | $112M | $140M |
| Earnings Per Share (EPS) | $0.18 | $0.19 | $0.11 | $0.01 | $0.07 | $0.04 | $-0.10 | $-0.00 |
| Shares Outstanding (M) | 328M | 329M | 325M | 325M | 322M | 324M | 310M | 310M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $201M | $340M | $295M | $346M | $65M | $242M | $379M | $2M | $250M | $234M | $115M | $105M | $112M |
| Capital Expenditures (CapEx) | $118M | $70M | $75M | $69M | $91M | $48M | $62M | $97M | $97M | $114M | $125M | $117M | $79M |
| Free Cash Flow (FCF) | $83M | $270M | $220M | $276M | ($25M) | $194M | $317M | ($96M) | $153M | $120M | ($10M) | ($12M) | $33M |
| FCF Margin % | 2.7% | 8.9% | 7.9% | 11.6% | -1.1% | 9.3% | 15.9% | -5.9% | 9.2% | 11.6% | -0.9% | -1.4% | 4.2% |
| Dividends Paid | — | — | — | — | $4M | — | — | $0M | $183M | $375M | $201M | $258M | $243M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($19M) | ($29M) | $130M | $118M | $84M | $7M | $118M | $142M |
| Capital Expenditures (CapEx) | $46M | $14M | $43M | $15M | $27M | $18M | $23M | $21M |
| Free Cash Flow (FCF) | ($65M) | ($43M) | $87M | $103M | $57M | ($11M) | $95M | $121M |
| FCF Margin % | -8.2% | -5.9% | 10.7% | 13.2% | 7.9% | -1.6% | 13.0% | 17.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.8B | $3.7B | $3.5B | $3.5B | $3.8B | $3.9B | $4.0B | $3.7B | $4.4B | $1.3B | $1.2B | $1.0B | $1.9B |
| Cash & Cash Equivalents | $128M | $311M | $111M | $92M | $26M | $248M | $341M | $151M | $213M | $74M | $27M | $61M | — |
| Total Liabilities | $3.7B | $3.7B | $3.5B | $3.4B | $3.6B | $3.6B | $3.6B | $3.3B | $3.5B | $1.7B | $1.4B | $1.2B | — |
| Total Debt (Short + Long-Term) | $2.7B | $2.6B | $2.5B | $2.7B | $2.7B | $2.7B | $2.8B | $2.6B | $2.7B | $1.4B | $851M | $484M | $0M |
| Total Shareholders' Equity | $33M | ($71M) | ($109M) | $20M | $298M | $360M | $303M | $232M | $896M | ($386M) | ($185M) | ($195M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AMRX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms